



Contact:

Mia West

West Public Relations LLC

mwest@west-pr.com

619.501.2756

Frequentz Inc. and Global Pharmaceutical Leaders Tackle Serialization and Compliance Issues at Stanford University

Palo Alto, CA – May 27, 2015 – Key representatives from the largest life sciences companies, including Baxter, McKesson and Cardinal, recently gathered for Frequentz Inc.'s 2015 Customer Advisory Council at Stanford University to tackle pressing **serialization** and **compliance** issues. The meeting yielded several key insights surrounding awareness and adoption of **EPCIS**, the timing and implementation of **DSCSA**, and Frequentz's ability to support upcoming regulations across the globe such as those in Brazil. Frequentz, Inc., a global leader of end-to-end visibility and traceability solution provider to companies that touch over 67 percent of the U.S. pharmaceutical volume, collaborated with their partners as part of their commitment to creating customized, forward-thinking **track and trace systems** that meet an individual company's needs.

"We have to know where we have been and how we got here to understand where we are going and what obstacles we will have to face in the future," said Ann Berkey, CEO of The Berkey Group, and former SVP, Public Affairs, McKesson.

The roundtable discussion focused on industry position and marketplace trends; the prioritization of immediate needs for growth of all stakeholders; the future enhancements and benefits of Frequentz's product roadmap; and the requirements needed to meet current regulatory compliances. Key takeaways include:

- EPCIS is the best option and most widely accepted industry standard for serialization
- Pharma companies will most likely need to run parallel paths of both ASN and EPCIS to eliminate issues as they approach deadlines in 2017 and beyond
- Requiring early education and adoption will stabilize implementation and ensure success
- In advance of 2017 regulatory deadlines, companies must begin engineering and implementing compliant serialization pilot programs now
- Numerous business efficiencies beyond compliance can be realized in the pharmaceutical supply chain once serialization has begun.



- Sharing manufacturer aggregation data with trading partners can help ease the process of meeting deadlines

With DSCSA regulations beginning to rollout this year, ensuring compliance with the law is imperative for continuing “business as usual.” Frequentz’s serialization and traceability solutions can help suppliers and their trading partners maintain “business as usual,” by offering an easy integration and rapid deployment of Frequentz’s software platform into their facilities. As the traceability vendor for several of the world’s largest life sciences companies, Frequentz offers a tested and specialized solution for transitioning from lot-level traceability to unit-level serialization, to comply with upcoming 2017 DSCSA requirements. Their GS1 Certified, EPCIS 1.1 compliant repository has been in use since 2007 and is the most advanced, ERP-agnostic software on the market.

About Frequentz

Frequentz is a global leader and champion of end-to-end visibility, offering comprehensive traceability, serialization and information management technologies. Their transformative tools bolster businesses and brand reputations by improving productivity, product quality, and profitability. To accomplish this, Frequentz provides valuable insight into end-to-end supply chains, and critical business processes by collecting, storing and analyzing serialized, life history data. Applications of its software are currently used in the life sciences, agricultural, fishery and sustainability, retail, and automotive industries worldwide and promote intelligent analytics and consumer safety. For more information visit www.frequentz.com.

###